Although GLP-1 drugs offer many health benefits, their high cost has created an affordability crisis for patients. With a ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

FROM eggy burps to stomach-churning nausea, there appears to be an endless list of side effects linked to Ozempic-like jabs. But now, experts are getting candid on a fat jab complication that ...

A fresh crop of facelift patients is seeking beauty not youth—and redefining the century-old plastic surgery procedure in the ...